Pituitary & hypothalamus

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis

PituitaryPublished Meta-analysis

Pooled result · Postoperative endocrinological remissionResult — go to the resultOR for endocrinological remission 0.60 95% CI 0.40–0.90

Authors' conclusion

SGST and DGST were demographically, clinicopathologically, and molecularly different from each other with the former associated with adverse treatment outcomes and poor response to medical therapy. There are still gaps in translational studies that could help us better understand the behavior of these tumors and identify potential targets in the treatment of sparsely granulated tumors.

Study context

Population
Somatotroph adenomas/tumors of the pituitary; studies from two electronic databases
Comparison
Sparsely granulated vs densely granulated somatotroph adenoma/tumor
Outcome
Postoperative endocrinological remission
Follow-up
Postoperative
Methodological detailsrandom-effects model
  • Random-effects model

Pooled result

As reported in the abstract

OR for endocrinological remission

0.60

95% CI 0.40–0.90

P = 0.01

SGSTvs DGST
OR for endocrinological remission 0.60 (95% CI 0.40–0.90); P = 0.01

Further pooled results

OutcomeOR (95% CI)P value
Response to SRL · postoperative follow-upPoorer response with SGST0.16 (0.08–0.35)P < 0.001
Prevalence of GSP mutations0.36 (0.17–0.79)P = 0.01

Demographics

SGST associated with younger age and lower male-to-female ratio vs DGST
P < 0.001

Tumor size and extension

SGST had larger tumor size and higher rate of cavernous sinus and suprasellar extension vs DGST
P < 0.001

Original publication

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis. Pituitary. Published 21 September 2023. doi:10.1007/s11102-023-01353-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.